Expiration of warrants
EDX Medical Group plc announces the expiration of all warrants as of June 3rd, 2026, with one warrant holder exercising their rights to issue 150,000 new ordinary shares at 10p each, expected to commence trading on AIM on June 9th, 2026. Following this issuance, the Company's total ordinary shares in issue will be 411,994,583, serving as a new denominator for shareholders' disclosure obligations under FCA rules.
Select text to share a quote on X · sign in to keep highlights & notes in your EDX notes
CAMBRIDGE, UK: EDX Medical Group plc (AIM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces the expiration of all warrants over ordinary shares in EDX Medical as of 5pm yesterday, June 3rd, 2026, in accordance with the terms of the warrant instrument.
Prior to the expiration deadline, one warrant holder exercised their rights resulting in the issue of 150,000 new ordinary shares at an exercise price of 10p per ordinary share. Application has been made for 150,000 ordinary shares to be admitted to trading on AIM and it is expected that trading will commence on 9 June 2026.
Following this issue of ordinary shares the Company will have 411,994,583 ordinary shares in issue. This figure may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company or its Group under the FCA's Disclosure and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.